Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. junior Avg
|
New words:
AKP, American, APIC, Asahi, ASCO, Asia, attractive, authority, boundary, candidate, Cardiology, cetuximab, clarify, cleaning, cobimetinib, coBRIM, consolidated, CRC, crossed, dabrafenib, database, decision, demonstrated, docetaxel, dollar, dose, dual, efficacy, employer, encouraging, FDA, fever, forfeited, futility, GI, HR, important, incidence, Kasei, key, learned, lease, lessee, locally, lock, longer, low, men, NSCLC, OS, pain, percent, photosensitivity, poor, predefined, principle, profile, prognostic, protocol, published, pyrexia, range, rash, receptor, resolution, showed, statistically, statutory, therapy, tolerability, Topic, trametinib, TrkA, twelve, vast, vemurafenib, withheld, withhold, withholding, women
Removed:
enroll
Filing tables
Filing exhibits
Related press release
Array similar filings
Filing view
External links